HELP: Cybin Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Cybin Inc.

NASDAQ:HELP

SummaryFactSheetFinancial
Price
$4.58
Loss Chance
58.9%
0.61JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
ANI Pharmaceuticals
NASDAQ:ANIP
4.95
$80.52
55.53%
Bausch Health Companies
NYSE:BHC
5.05
$4.76
82.66%
Collegium Pharmaceutical
NASDAQ:COLL
5.69
$33.68
90.28%
GSK plc
NYSE:GSK
6.96
$52.15
44.46%
Harmony Biosciences Holdings
NASDAQ:HRMY
6.05
$33.77
31.35%
Jitta Factors
Growth Opportunity (3)
Recent Business Performance (17)
Financial Strength (33)
Return to Shareholders (0)
Competitive Advantage (4)
Jitta Signs
Cash Conversion CycleLess than 30 days
Recent Business PerformanceEarning decline 194.66% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
0.61
100.00%
3.06
203.75%
3.05
146.31%
Pharmaceuticals
4.95
55.53%
5.05
82.66%
5.69
90.28%
COMPANY DESCRIPTION
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
cybin.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.